Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bexion Pharmaceuticals doses first patient in new cancer clinical study
A Northern Kentucky startup developing targeted therapies for cancer has dosed its first patient in a clinical study being held in Cincinnati.
Covington-based Bexion Pharmaceuticals, a clinical-stage biopharma company, said Tuesday it dosed its first adult patient in the new study for BXQ-350, its lead drug candidate.
The study, known as RETRO, will assess the potential for BXQ-350 to reduce the intensity and/or duration of chemotherapy-induced peripheral neuropathy, or CIPN, a common side effect… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 19, 2022 Category: Health Management Authors: Liz Engel Source Type: news
Acute peripheral neuropathy following animal envenomation: a case report and systematic review - Mathis S, Carla L, Duval F, Nadal L, Sol é G, Le Masson G.
Animal envenomation in humans is usually accidental or for defensive purposes. Depending on the venom composition and administration, different reactions can be observed. After reporting the first case of acute polyradiculitis in a 57-year-old healthy male... (Source: SafetyLit)
Source: SafetyLit - October 18, 2022 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news
Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk-The walk2Wellness trial - Oddsson LIE, Bisson T, Cohen HS, Iloputaife I, Jacobs L, Kung D, Lipsitz LA, Manor B, McCracken P, Rumsey Y, Wrisley DM, Koehler-McNicholas SR.
BACKGROUND: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins( ®), a wearable lower limb sensory pros... (Source: SafetyLit)
Source: SafetyLit - October 10, 2022 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news
Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer
(MedPage Today) -- PARIS -- Hand cooling and compression each cut the risk of high-grade chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing treatment for primary breast cancer, according to the first prospective trial comparing... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 15, 2022 Category: Hematology Source Type: news
Cancer - Related Fatigue in Women With Breast Cancer May Affect Balance
Greater CRF predicts increased pre - and postexertional static sway, while chemo - induced peripheral neuropathy does not (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 1, 2022 Category: Cancer & Oncology Tags: Gynecology, Internal Medicine, Neurology, Oncology, Pharmacy, Radiology, Journal, Source Type: news
Cancer-Related Fatigue in Women With Breast Cancer May Affect Balance
THURSDAY, Sept. 1, 2022 -- For women who have completed treatment for breast cancer, persistent cancer-related fatigue appears to influence balance, independent of chemotherapy-induced peripheral neuropathy (CIPN) symptoms, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2022 Category: Pharmaceuticals Source Type: news
Screen COPD Patients for Peripheral Neuropathy Screen COPD Patients for Peripheral Neuropathy
Authors of a current review acknowledge treatment limitations but found a high prevalence of peripheral neuropathy among patients with COPD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2022 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Nerve damage: The popular food item that can have a ‘harmful effect’ on the sciatic nerve
NERVE damage, scientifically known as peripheral neuropathy, can become fatal if left unmanaged. Common triggers of neuropathy include traumatic injury and vitamin deficiencies, but among the lesser-known triggers may be long-term exposure to one popular ingredient. (Source: Daily Express - Health)
Source: Daily Express - Health - August 21, 2022 Category: Consumer Health News Source Type: news
Neuropathy Drives Hypoglycemia Cluelessness in T1D Neuropathy Drives Hypoglycemia Cluelessness in T1D
People with type 1 diabetes may be unaware of hypoglycemia episodes because of peripheral neuropathy, while insulin pump use and higher problem-solving perception each linked with improved awareness.First Look (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - August 1, 2022 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news
Every Day, I Live My Life in Pain
(MedPage Today) -- In 1982, at the age of 31, I was diagnosed with a small-fiber length-dependent sensory peripheral neuropathy. Despite extensive laboratory assessments (including genome sequencing), the cause is unknown. Most patients with small... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 6, 2022 Category: Psychiatry Source Type: news
He Could Barely Walk and Had to Give Up Golf. What Was Wrong?
Over six years, many doctors told the patient he had peripheral neuropathy. What they couldn ’t tell him was why — or how to treat it. (Source: NYT Health)
Source: NYT Health - June 30, 2022 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Golf Tests (Medical) Nerves and Nervous System Immune System Source Type: news
' Genetic' Height Linked to Peripheral Neuropathy, Other Disorders'Genetic' Height Linked to Peripheral Neuropathy, Other Disorders
' Genetic ' height, the height a person is predicted to reach independent of environmental influences, may be an underappreciated risk factor for a wide range of chronic conditions, new research suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
